Log in
NYSE:ZYME

Zymeworks Stock Forecast, Price & News

$49.86
+1.31 (+2.70 %)
(As of 11/27/2020 12:00 AM ET)
Add
Compare
Today's Range
$48.21
Now: $49.86
$52.60
50-Day Range
$39.12
MA: $43.22
$48.55
52-Week Range
$20.33
Now: $49.86
$52.75
Volume307,088 shs
Average Volume441,166 shs
Market Capitalization$2.29 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.75
Zymeworks Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer. The company's lead product candidates include ZW25, a bispecific antibody that is in Phase I and Phase II clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and other tumors; and ZW49, a bispecific antibody-drug conjugate that is in Phase I clinical trial for the treatment of advanced or metastatic HER2-expressing cancers. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; collaboration with Applied BioMath, LLC.; and a research collaboration with ImmunoPrecise Antibodies Ltd. for the development of multiple antibody candidates to fight COVID-19. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Read More
Zymeworks logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.19 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Previous SymbolNASDAQ:ZYME
CUSIPN/A
Phone604-678-1388
Employees325

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$29.54 million
Book Value$6.21 per share

Profitability

Net Income$-145,440,000.00
Net Margins-569.13%

Miscellaneous

Market Cap$2.29 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$49.86
+1.31 (+2.70 %)
(As of 11/27/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ZYME News and Ratings via Email

Sign-up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Zymeworks (NYSE:ZYME) Frequently Asked Questions

How has Zymeworks' stock been impacted by Coronavirus?

Zymeworks' stock was trading at $32.26 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ZYME shares have increased by 54.6% and is now trading at $49.86.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Zymeworks?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zymeworks in the last year. There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zymeworks
.

What stocks does MarketBeat like better than Zymeworks?

Wall Street analysts have given Zymeworks a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Zymeworks wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Zymeworks' next earnings date?

Zymeworks is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Zymeworks
.

How were Zymeworks' earnings last quarter?

Zymeworks Inc. (NYSE:ZYME) issued its earnings results on Tuesday, November, 3rd. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.89) by $0.54. The firm earned $2.64 million during the quarter, compared to the consensus estimate of $12.13 million. Zymeworks had a negative return on equity of 44.06% and a negative net margin of 569.13%.
View Zymeworks' earnings history
.

What price target have analysts set for ZYME?

11 Wall Street analysts have issued 1 year target prices for Zymeworks' shares. Their forecasts range from $42.00 to $70.00. On average, they expect Zymeworks' share price to reach $52.91 in the next year. This suggests a possible upside of 6.1% from the stock's current price.
View analysts' price targets for Zymeworks
.

Are investors shorting Zymeworks?

Zymeworks saw a decline in short interest in the month of October. As of October 30th, there was short interest totaling 1,480,000 shares, a decline of 21.7% from the October 15th total of 1,890,000 shares. Based on an average trading volume of 416,400 shares, the days-to-cover ratio is presently 3.6 days. Currently, 3.8% of the shares of the company are sold short.
View Zymeworks' Short Interest
.

Who are some of Zymeworks' key competitors?

What other stocks do shareholders of Zymeworks own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zymeworks investors own include Advanced Micro Devices (AMD), Gilead Sciences (GILD), Just Energy Group (JE), NVIDIA (NVDA), Just Energy Group Inc. (JE.TO) (JE), PayPal (PYPL), Alibaba Group (BABA), Cronos Group (CRON), CRISPR Therapeutics (CRSP) and Tesla (TSLA).

Who are Zymeworks' key executives?

Zymeworks' management team includes the following people:
  • Dr. Ali Tehrani, Co-Founder, Pres, CEO & Director (Age 48, Pay $902.94k)
  • Dr. Anthony J. Polverino, Chief Scientific Officer & Exec. VP of Early Devel. (Age 57, Pay $578.38k)
  • Ms. Kathryn O'Driscoll, Chief People Officer (Age 56, Pay $108.89k)
  • Dr. Diana F. Hausman, Chief Medical Officer (Age 57, Pay $646.51k)
  • Dr. Neil Josephson M.D., Sr. VP of Clinical Research
  • Mr. Neil A. Klompas C.A., CPA, CPA, CA, Exec. VP of Bus. Operations & CFO (Age 48)
  • Dr. Surjit Dixit, VP of Technology (Age 47)
  • Mr. Daniel Dex, VP of Legal & Corp. Sec.
  • Mr. John Babcook, Sr. VP of Discovery Research (Age 57)
  • Mr. Mark Hollywood, Sr. VP of Technical & Manufacturing Operations (Age 51)

When did Zymeworks IPO?

(ZYME) raised $65 million in an IPO on Friday, April 28th 2017. The company issued 4,500,000 shares at $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity acted as the underwriters for the IPO and Cormark Securities was co-manager.

What is Zymeworks' stock symbol?

Zymeworks trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZYME."

Who are Zymeworks' major shareholders?

Zymeworks' stock is owned by a number of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.60%), Great Point Partners LLC (3.42%), UBS Asset Management Americas Inc. (1.40%), Vivo Capital LLC (1.40%), Candriam Luxembourg S.C.A. (1.36%) and Wells Fargo & Company MN (1.04%). Company insiders that own Zymeworks stock include Ali Tehrani, David Kai Yuen Poon, Diana Hausman, Eli & Co Lilly, Neil A Klompas and Troy Cox.
View institutional ownership trends for Zymeworks
.

Which major investors are selling Zymeworks stock?

ZYME stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC, First Light Asset Management LLC, Sofinnova Investments Inc., Morgan Stanley, Vivo Capital LLC, Picton Mahoney Asset Management, Sphera Funds Management LTD., and Victory Capital Management Inc.. Company insiders that have sold Zymeworks company stock in the last year include Ali Tehrani, and Diana Hausman.
View insider buying and selling activity for Zymeworks
.

Which major investors are buying Zymeworks stock?

ZYME stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Candriam Luxembourg S.C.A., UBS Asset Management Americas Inc., Point72 Asset Management L.P., Thrivent Financial for Lutherans, Wells Fargo & Company MN, Raymond James & Associates, and State Street Corp. Company insiders that have bought Zymeworks stock in the last two years include Ali Tehrani, and Troy Cox.
View insider buying and selling activity for Zymeworks
.

How do I buy shares of Zymeworks?

Shares of ZYME can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zymeworks' stock price today?

One share of ZYME stock can currently be purchased for approximately $49.86.

How big of a company is Zymeworks?

Zymeworks has a market capitalization of $2.29 billion and generates $29.54 million in revenue each year. The company earns $-145,440,000.00 in net income (profit) each year or ($3.83) on an earnings per share basis. Zymeworks employs 325 workers across the globe.

What is Zymeworks' official website?

The official website for Zymeworks is www.zymeworks.com.

How can I contact Zymeworks?

Zymeworks' mailing address is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. The company can be reached via phone at 604-678-1388 or via email at [email protected]

This page was last updated on 11/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.